Eating without fear: A single vaccine against multiple food allergies
en-GBde-DEes-ESfr-FR

Eating without fear: A single vaccine against multiple food allergies


DTU researchers have taken an important step towards treating a range of common allergies at once using a vaccine. They are now in the process of refining the vaccine and preparing to test it in humans.

According to UN figures, more than 220 million people worldwide suffer from food allergies, which cause the body to perceive an otherwise harmless protein in food as dangerous. As a result, the immune system launches an attack on the protein (see fact box), which in the worst cases can be life-threatening.

In the only treatment currently capable of potentially curing people’s allergies, patients are exposed over several years—via injections or tablets—to increasing amounts of the protein (allergen) they cannot tolerate, so the body gradually gets used to it.

However, due to the hassle and discomfort of the treatment, many people choose “simply” to avoid the substances to which they are allergic, as well as anything that might trigger a cross-reaction (see fact box).

A Trojan horse

As an alternative, researchers at DTU have developed a vaccine that contains a synthetic allergen. The allergen shares common features with several related and widespread allergens found, for example, in peaches and certain nuts.

The vaccine is designed to reprogramme the body’s immune system so that, upon encountering these related allergens, it produces protective antibodies that can recognize and block the allergens before they have a chance to trigger an allergic reaction.

“The idea is that if you are allergic to several different things, all of which have roughly the same molecular structure, we can take this structure and produce an artificial allergen, which we then incorporate into a vaccine,” explains Associate Professor Esperanza Rivera de Torre from DTU Bioengineering.

The researchers are using an mRNA vaccine like those we came to know during the COVID-19 pandemic.

“We use the mRNA as a Trojan horse: Instead of giving the patient the actual allergen and building up the body’s tolerance to it, we use the vaccine to give the body instructions on how to handle the allergen correctly, thereby avoiding an allergic reaction. My hope is that patients will be able to eat whatever they like without having to check the ingredients list,” she explains.

Good protection

The researchers have studied the effect of the vaccine in both healthy and allergic mice in a study whose promising results were published in a scientific article in Nature Communications in February 2026.

After the first dose of the vaccine, the healthy mice produced large quantities of protective antibodies. After three doses administered at three-week intervals, the mice were exposed to a range of the allergens against which the vaccine is designed to provide protection. The study showed that the vaccination had elicited a strong antibody response, providing broad coverage against the allergens.

In the allergic mice, the researchers also recorded a marked increase in the production of antibodies that protect against the range of allergens, while virtually no side effects of the vaccine were observed. However, it did not provide full protection against anaphylaxis at the concentration and number of doses tested.

The researchers also carried out laboratory experiments using cells and blood from both allergic patients and the vaccinated mice. The analyses show that the protective antibodies produced by the mice were able to prevent allergic reactions in the patients.

“If you can induce such antibody responses in mice, then there is also a very good chance that you can do so in humans. And if they protect the mice against allergic reactions, then there is also a good chance that they will provide protection in humans,” explains PhD student and lead author of the scientific article, Mark Møiniche.

All in all, the researchers’ work on the vaccine constitutes a proof of concept—that is, evidence that the idea is technically feasible. With a grant of five mio. Danish kroner from the Lundbeck Foundation, they are now working, amongst other things, on refining the lipid bubbles in which the immune-activating allergen is encapsulated before it is incorporated into the vaccine.

“You can swap out different parts of the lipids, depending on how you want to tweak the immune system to elicit a specific response or perhaps avoid a particular response,” Mark Møiniche explains.

The researchers are also planning studies in a larger group of mice to, amongst other things, gain a better understanding of how often the vaccine should be administered, and in what doses, to achieve full protection—including against anaphylaxis.

The current vaccine targets several related allergens that are particularly widespread in southern Europe, and which can cause cross-reactions upon consumption of a wide range of fruits. However, the researchers expect that the concept can be applied to other classes of cross-reactive allergens.

They are therefore also working on developing a consensus allergen that can provide protection against exposure to another group of allergens, found e.g., in apples, carrots and hazelnuts.

The researchers’ overarching aim with this latest grant is to generate the data required to obtain approval to test the vaccine in humans.

-
Fact Box

Allergic reactions

A food allergy occurs when a person eats something and their immune system overreacts to specific proteins (allergens) in the food by producing a certain type of antibody.

Upon subsequent exposure to the allergen, these antibodies will, in response, trigger the release of histamines, which can cause allergic reactions ranging from a runny nose or vomiting to potentially life-threatening anaphylactic shock.

Many people also experience an allergic reaction upon contact with allergens that are “related” to the allergens they cannot tolerate. These so-called cross-reactions are usually on the milder end of the spectrum.

Source: lex.dk and sundhed.dk

About the development of the vaccine

For their work, the researchers received funding from DTU, the Innovation Fund and the Lundbeck Foundation—most recently in July 2026, when Esperanza Rivera de Torre received a Frontier Grant of 5 mio. Danish kroner from the latter.

In the 18-month project, researchers at DTU are collaborating with colleagues from Eindhoven University of Technology and IBIMA Plataforma BIONAND.

Snakes and allergies

The idea for the allergy vaccine was inspired by DTU’s pioneering work on developing a broad-spectrum antivenom against snake venom, which has shown impressive potential in preclinical trials. The idea came to Esperanza Rivera de Torre while she was working on the project under the supervision of Professor and Head of Section Andreas Hougaard Laustsen-Kiel.

“It made me think: If we can find a molecule that can make the body neutralize a range of different snake venoms, perhaps we can do the same with allergens,” she explains, continuing:

“That is precisely what makes DTU unique: They encourage you to think about the challenges we face today and how you can use your skills to solve them.”

DTU has applied for a patent for the vaccine invention, which is expected to be used under license by a spin-off company founded by the two researchers

Attached files
  • This graphic, created by DTU researchers using ChimeraX, shows a range of so-called LTP allergens, as well as—on the far left—the synthetic allergen, which contains common features of the other allergens. Source: DTU
Regions: Europe, Denmark
Keywords: Health, Food, Medical, People in health research, Science, Life Sciences

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2026 by AlphaGalileo Terms Of Use Privacy Statement